Welcome to our dedicated page for Tiziana Life Sciences Com SEC filings (Ticker: TLSA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Tiziana Life Sciences Ltd. (NASDAQ: TLSA) SEC filings page provides access to the company’s official regulatory disclosures as a foreign private issuer. Tiziana files its annual report on Form 20-F and furnishes current reports on Form 6-K under the Securities Exchange Act of 1934. These filings include press releases and formal updates on clinical, regulatory, and corporate developments.
For investors analyzing Tiziana’s clinical-stage biopharmaceutical business, Form 6-K reports are particularly important. Recent 6-Ks have furnished announcements about the dosing of the first patient in a Phase 2 randomized, placebo-controlled trial of intranasal foralumab in early Alzheimer’s disease, the initiation of enrolment for that trial, and the inclusion of the company’s ALS Phase 2 study in the ALS MyMatch Program. Other 6-K filings describe insider share purchases by the Chief Executive Officer, the withdrawal of a proposed public offering of common shares due to market conditions, interim financial results and corporate updates on lead programs, and participation in global healthcare conferences.
Tiziana also reports on safety and regulatory interactions for intranasal foralumab, including Development Safety Update Reports submitted to the U.S. Food and Drug Administration that summarize cumulative exposure and serious adverse event findings across neuroinflammatory indications. While these safety reports themselves are submitted to regulators, related information may be discussed in filed or furnished documents.
On this page, users can review Tiziana’s 20-F annual report for a comprehensive overview of its business and risk factors, and track ongoing 6-K filings for timely information on clinical milestones, strategic plans such as the intended spinout of IL-6 asset TZLS-501, and capital markets activities. Stock Titan enhances these filings with AI-powered summaries that explain key points from lengthy documents, highlight material disclosures, and make it easier to understand how each filing may relate to Tiziana’s intranasal immunotherapy programs and overall corporate strategy.
Tiziana Life Sciences reported that Founder and Executive Chairman Gabriele Cerrone will ring the Nasdaq Closing Bell at the Nasdaq MarketSite in Times Square, New York, on December 17, 2025. The ceremony, held from 3:45 PM to 4:15 PM ET, celebrates the company’s ongoing work on intranasal foralumab, a fully human anti-CD3 monoclonal antibody delivered through the nose. This lead candidate and its nasal delivery approach aim to improve efficacy, safety, and tolerability versus traditional intravenous methods for neurodegenerative and inflammatory diseases such as multiple sclerosis, Alzheimer’s disease, and ALS.
Tiziana Life Sciences LTD reported that the first patient has been dosed with intranasal foralumab in its Phase 2 randomized, placebo-controlled clinical trial in patients with early Alzheimer’s disease. This milestone comes shortly after enrollment began, when the first patient was expected to be dosed imminently. The Phase 2 study is evaluating intranasal foralumab both as a standalone treatment and in combination with FDA-approved anti-amyloid therapies lecanemab (Leqembi) or donanemab in early Alzheimer’s patients.
Tiziana Life Sciences LTD reported that its Chief Executive Officer, Ivor Elrifi, bought 163,400 shares of Tiziana common stock in the open market on December 15, 2025. These purchases increase his total open-market purchased holdings to 357,848 shares.
This move means the company’s top executive has committed more of his own capital to Tiziana’s stock, which some investors view as a sign of confidence in the business. The disclosure is provided in a Form 6-K, with an accompanying press release furnished as Exhibit 99.1.
Tiziana Life Sciences LTD filed a Form 6-K stating that it has withdrawn its proposed public offering of common shares due to market conditions.
The company furnished a press release dated December 15, 2025 as Exhibit 99.1, and specified that this material is being furnished, not deemed filed or automatically incorporated into other securities law filings.
Tiziana Life Sciences Ltd. is conducting a primary best-efforts offering of common shares on Nasdaq to raise cash for its clinical-stage neurology pipeline. ThinkEquity LLC is acting as exclusive placement agent, but is not required to place any minimum number of shares, there is no minimum offering amount and no escrow account, so any funds received will be available to the company immediately.
The company plans to use net proceeds, together with existing cash, mainly to advance its lead candidate foralumab in non-active secondary progressive multiple sclerosis, Alzheimer’s disease and multiple system atrophy, and for working capital, capital spending and general corporate purposes. Because the offering price will be above the company’s net tangible book value, new investors are expected to incur immediate and substantial dilution, and future equity or debt financings could create additional dilution or restrictions. The prospectus also highlights volatility in TLSA’s share price and the likelihood that Tiziana will need further capital even after this offering.
Tiziana Life Sciences LTD reports that enrollment has begun in its Phase 2 randomized, placebo-controlled clinical trial in patients with early Alzheimer’s disease. The study is testing intranasal foralumab, an experimental therapy, both on its own and together with FDA‑approved anti‑amyloid drugs lecanemab or donanemab.
The company plans to dose the first patient next week, indicating the trial is moving from screening into active treatment. Baseline clinical assessments, cognitive testing, TSPO‑PET brain imaging, and fluid biomarker measurements have already been completed for the first participants, laying the groundwork to track how patients respond over time.
Tiziana Life Sciences (TLSA) reported that its Phase 2 clinical trial of intranasal foralumab in patients with amyotrophic lateral sclerosis (ALS) has been accepted into the ALS MyMatch Program at the Sean M. Healey & AMG Center for ALS at Mass General Brigham. This places the company’s ALS study within a coordinated clinical research framework focused on the disease. The update is structured as an informational report and does not include financial results or transaction details.
Tiziana Life Sciences (TLSA) furnished a Form 6-K stating its senior leadership will present a corporate overview at the Jefferies London Healthcare Conference. Chief Executive Officer Ivor Elrifi and Chief Operating Officer/Chief Financial Officer Keeren Shah will highlight the company’s innovative pipeline and recent clinical milestones.
The accompanying press release is included as Exhibit 99.1. The information is furnished, not filed, under the Exchange Act and is not incorporated by reference except as specifically stated.
Tiziana Life Sciences (TLSA) announced it will participate as a presenting company at BIO-Europe 2025, described as Europe’s premier life sciences partnering conference.
The event will be held November 3–5, 2025, at the Vienna Exhibition and Congress Center (Messe Wien) in Vienna, Austria. The related press release was furnished as Exhibit 99.1 and is not deemed filed under Section 18 of the Exchange Act.
Tiziana Life Sciences LTD submitted a Form 6-K to furnish its interim financial results for the six months ended June 30, 2025 and to provide a corporate update on its lead development programs. These details are contained in an accompanying announcement labeled Exhibit 99.1. The information in that exhibit is treated as furnished rather than filed under U.S. securities laws, which affects how related legal liabilities apply. The company also states that this Form 6-K, including Exhibit 99.1, is incorporated by reference into its existing shelf registration statement on Form F-3, allowing the interim results and corporate update to be part of the disclosure package for any future securities offerings under that registration.